FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000462852> ?p ?o ?g. }

• W2000462852 endingPage "1167" @default.
• W2000462852 startingPage "1161" @default.
• W2000462852 abstract "Objective: To evaluate the toxicity and the maximum tolerated dose (MTD) of paclitaxel concurrently with three-dimensional (3D) conformal radiotherapy for patients with locally advanced non-small cell lung cancer (LANSCLC) after 2–3 cycles of induction chemotherapy.Research design and methods: Patients with histologically proven stage III non-small cell lung cancer (NSCLC) were eligible. Induction chemotherapy regimen included cisplatin (40 mg/m2) on days 1 and 2, and vinorelbine (25 mg/m2) on days 1 and 8 every 3 weeks for 2 or 3 cycles, followed a month later by continual three-dimensional (3D) conformal radiotherapy (60 Gy in 30 fractions for 6 weeks) delivered concurrently with paclitaxel dose escalating from the lowest level, 15 mg/m2, twice weekly, 6 weeks in all, to the highest level, 15 mg/m2, three times a week, 6 weeks in all.Main outcome measures: The MTD was defined as the highest safely tolerated dose at which no more than one patient out of six experiences dose-limiting toxicity, with the next higher dose having at least two out of six patients experience dose-limiting toxicity (DLT).Results: Twenty-three patients were enrolled in this study. The maximum tolerated dose of paclitaxel during 3D-conformal radiotherapy was not reached at 15 mg/m2, three times a week, 6 weeks in all, a level which has been recommended for Caucasian patients with LANSCLC without induction chemotherapy. The overall response rate of induction chemotherapy alone was 47.8% (0% complete remission, 47.8% partial remission, 39.1% stable disease, 13% progressive disease) and that of induction chemotherapy plus concurrent treatment was 78.3% (18/23), including 8.7% (2/23) complete remissions. None of the patients died as a result of toxicity. The median survival time was 23.0 months.Conclusions: 15 mg/m2 of paclitaxel, three times a week, concurrently with 3D-conformal radiotherapy for patients with locally advanced NSCLC after 2 or 3 cycles of induction chemotherapy is a safe and effective dose, according to our preliminary study." @default.
• W2000462852 created "2016-06-24" @default.
• W2000462852 creator A5002059103 @default.
• W2000462852 creator A5012643854 @default.
• W2000462852 creator A5012796164 @default.
• W2000462852 creator A5017330670 @default.
• W2000462852 creator A5030216533 @default.
• W2000462852 creator A5073436439 @default.
• W2000462852 creator A5077453513 @default.
• W2000462852 date "2007-04-19" @default.
• W2000462852 modified "2023-10-12" @default.
• W2000462852 title "Phase I study to determine the MTD of paclitaxel given three times per week during concurrent radiation therapy for stage III non-small cell lung cancer" @default.
• W2000462852 cites W1616592835 @default.
• W2000462852 cites W1781834802 @default.
• W2000462852 cites W1944220675 @default.
• W2000462852 cites W1964204964 @default.
• W2000462852 cites W1969561838 @default.
• W2000462852 cites W1973641691 @default.
• W2000462852 cites W1980923728 @default.
• W2000462852 cites W1989367285 @default.
• W2000462852 cites W2008318438 @default.
• W2000462852 cites W2009650722 @default.
• W2000462852 cites W2016691736 @default.
• W2000462852 cites W2026025667 @default.
• W2000462852 cites W2030169244 @default.
• W2000462852 cites W2048819950 @default.
• W2000462852 cites W2079298441 @default.
• W2000462852 cites W2084588173 @default.
• W2000462852 cites W2130111557 @default.
• W2000462852 cites W2138725715 @default.
• W2000462852 cites W2152520755 @default.
• W2000462852 cites W2155053061 @default.
• W2000462852 cites W2312703485 @default.
• W2000462852 cites W2405216709 @default.
• W2000462852 cites W2407507636 @default.
• W2000462852 cites W2413163579 @default.
• W2000462852 cites W2416290051 @default.
• W2000462852 cites W2504684570 @default.
• W2000462852 cites W2978050124 @default.
• W2000462852 cites W2994150720 @default.
• W2000462852 cites W2395938033 @default.
• W2000462852 cites W2409738087 @default.
• W2000462852 cites W2411088869 @default.
• W2000462852 doi "https://doi.org/10.1185/030079907x187874" @default.
• W2000462852 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17519083" @default.
• W2000462852 hasPublicationYear "2007" @default.
• W2000462852 type Work @default.
• W2000462852 sameAs 2000462852 @default.
• W2000462852 citedByCount "4" @default.
• W2000462852 countsByYear W20004628522016 @default.
• W2000462852 crossrefType "journal-article" @default.
• W2000462852 hasAuthorship W2000462852A5002059103 @default.
• W2000462852 hasAuthorship W2000462852A5012643854 @default.
• W2000462852 hasAuthorship W2000462852A5012796164 @default.
• W2000462852 hasAuthorship W2000462852A5017330670 @default.
• W2000462852 hasAuthorship W2000462852A5030216533 @default.
• W2000462852 hasAuthorship W2000462852A5073436439 @default.
• W2000462852 hasAuthorship W2000462852A5077453513 @default.
• W2000462852 hasConcept C121608353 @default.
• W2000462852 hasConcept C126322002 @default.
• W2000462852 hasConcept C126894567 @default.
• W2000462852 hasConcept C143998085 @default.
• W2000462852 hasConcept C146357865 @default.
• W2000462852 hasConcept C151730666 @default.
• W2000462852 hasConcept C2776256026 @default.
• W2000462852 hasConcept C2776611710 @default.
• W2000462852 hasConcept C2776694085 @default.
• W2000462852 hasConcept C2777292972 @default.
• W2000462852 hasConcept C2778239845 @default.
• W2000462852 hasConcept C2780350996 @default.
• W2000462852 hasConcept C2781413609 @default.
• W2000462852 hasConcept C29730261 @default.
• W2000462852 hasConcept C509974204 @default.
• W2000462852 hasConcept C71924100 @default.
• W2000462852 hasConcept C86803240 @default.
• W2000462852 hasConcept C90924648 @default.
• W2000462852 hasConceptScore W2000462852C121608353 @default.
• W2000462852 hasConceptScore W2000462852C126322002 @default.
• W2000462852 hasConceptScore W2000462852C126894567 @default.
• W2000462852 hasConceptScore W2000462852C143998085 @default.
• W2000462852 hasConceptScore W2000462852C146357865 @default.
• W2000462852 hasConceptScore W2000462852C151730666 @default.
• W2000462852 hasConceptScore W2000462852C2776256026 @default.
• W2000462852 hasConceptScore W2000462852C2776611710 @default.
• W2000462852 hasConceptScore W2000462852C2776694085 @default.
• W2000462852 hasConceptScore W2000462852C2777292972 @default.
• W2000462852 hasConceptScore W2000462852C2778239845 @default.
• W2000462852 hasConceptScore W2000462852C2780350996 @default.
• W2000462852 hasConceptScore W2000462852C2781413609 @default.
• W2000462852 hasConceptScore W2000462852C29730261 @default.
• W2000462852 hasConceptScore W2000462852C509974204 @default.
• W2000462852 hasConceptScore W2000462852C71924100 @default.
• W2000462852 hasConceptScore W2000462852C86803240 @default.
• W2000462852 hasConceptScore W2000462852C90924648 @default.
• W2000462852 hasIssue "5" @default.
• W2000462852 hasLocation W20004628521 @default.
• W2000462852 hasLocation W20004628522 @default.
• W2000462852 hasOpenAccess W2000462852 @default.

• next